Clinician Investigator Program (CIP Sample Clauses

Clinician Investigator Program (CIP a) For a maximum of two (2) years, Resident Physicians participating in the CIP shall be remunerated during each year of the CIP, and shall receive full benefits. b) For Resident Physicians registered in the CIP, the Pay Level for Resident Physicians during the CIP, and upon return to their regular residency program, will account for the total number of years of accredited training completed in both their regular residency program and the CIP, up to a maximum of the typical number of years required to compete certification in the applicable program as determined by the Faculties. For example, a Resident Physician who completes three (3) years of a regular five (5) year residency program before entering the CIP would be paid at Pay Level IV during the first year of the CIP and Pay Level V in the second year. Upon returning to the regular residency program, they would be paid at Pay Level V for the remaining two years of their residency program. c) During the CIP, Resident Physicians shall be required to continue to provide clinical services in their home program. This shall not exceed twenty (20) percent. d) While providing Resident Physician clinical services in their home program, Resident Physicians shall be eligible to receive Duty Hour Stipends in accordance with Article 35.05.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
Clinician Investigator Program (CIP a) For a maximum of two (2) years, Resident Physicians participating in the CIP shall be remunerated during each year of the CIP, and shall receive full benefits. b) For Resident Physicians registered in the CIP as of July 1, 2017, the Pay Level for Resident Physicians during the CIP, and upon return to their regular residency program, will account for the total number of years of accredited training completed in both their regular residency program and the CIP. For example, a Resident Physician who completes three (3) years of a regular five (5) year residency program before entering the CIP would be paid at Pay Level IV during the first year of the CIP and Pay Level V in the second year. Upon returning to the regular residency program, they would be paid at Pay Level VI during their first year back (4th year of the regular residency program) and at Pay Level VII for their final year. c) For Resident Physicians registered in the CIP after July 1, 2017, the Pay Level for Resident Physicians during the CIP, and upon return to their regular residency program, will account for the total number of years of accredited training completed in both their regular residency program and the CIP, up to a maximum of the typical number of years required to compete certification in the applicable program as determined by the Faculties. For example, a Resident Physician who completes three (3) years of a regular five (5) year residency program before entering the CIP would be paid at Pay Level IV during the first year of the CIP and Pay Level V in the second year. Upon returning to the regular residency program, they would be paid at Pay Level V for the remaining two years of their residency program.
Sample 1
Clinician Investigator Program (CIP a) For a maximum of two (2) years, Resident Physicians participating in the CIP shall be remunerated during each year of the CIP, and shall receive full benefits. b) For Resident Physicians currently registered in the CIP, the Pay Level for Resident Physicians during the CIP, and upon return to their regular residency program, will account for the total number of years of accredited training completed in both their regular residency program and the CIP. For example, a Resident Physician who completes three (3) years of a regular five (5) year residency program before entering the CIP would be paid at Pay Level IV during the first year of the CIP and Pay Level V in the second year. Upon returning to the regular residency program, they would be paid at Pay Level VI during their first year back (4th year of the regular residency program) and at Pay Level VII for their final year. Effective July 1, 2017, for Resident Physicians accepted into the CIP after date of ratification of this Agreement (September 25, 2017), the Pay Level for Resident Physicians during the CIP will be the Pay Level that they would have been promoted into had they remained in their regular residency program. For example, a Resident Physician who completes three (3) years of a regular five (5) year residency program before entering the CIP would be paid at Pay Level IV during the CIP and would recommence their regular residency program at Pay Level IV at the conclusion of the CIP. c) During the CIP, Resident Physicians shall be required to continue to provide clinical services in their home program. This shall not exceed twenty (20) percent.
Sample 1

Related to Clinician Investigator Program (CIP

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Investigator Where a difference arises between the parties relating to the dismissal, discipline or suspension of an employee, or to the interpretation, application, operation or alleged violation of this agreement, including any questions as to whether a matter is arbitrable, during the term of the collective agreement, an arbitrator agreed to by the parties shall, at the request of either party: (a) investigate the difference; (b) define the issue in the difference; and (c) make written recommendations to resolve the difference within five days of the date of receipt of the request and for those five days from that date time does not run in respect of the grievance procedure. The parties agree that this procedure will not be invoked until the grievance procedure has been completed.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • HEALTH PROGRAM 3701 Health examinations required by the Employer shall be provided by the Employer and shall be at the expense of the Employer. 3702 Time off without loss of regular pay shall be allowed at a time determined by the Employer for such medical examinations and laboratory tests, provided that these are performed on the Employer’s premises, or at a facility designated by the Employer. 3703 With the approval of the Employer, a nurse may choose to be examined by a physician of her/his own choice, at her/his own expense, as long as the Employer receives a statement as to the fitness of the nurse from the physician. 3704 Time off for medical and dental examinations and/or treatments may be granted and such time off, including necessary travel time, shall be chargeable against accumulated income protection benefits.

  • Research Primary Investigator as part of a multi-site study (25 points) • Co-Investigator as part of a multi-site study (20 points) • Primary Investigator of a facility/unit based research study (15 points) • Co-Investigator of a facility/unit based research study (10 points) • Develops a unit specific research proposal (5 points) • Conducts a literature review as part of a research study (5 points)

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Professional Development Program (a) The parties agree to continue a Professional Development Program for the maintenance and development of the faculty members' professional competence and effectiveness. It is agreed that maintenance of currency of subject knowledge, the improvement of performance of faculty duties, and the maintenance and improvement of professional competence, including instructional skills, are the primary professional development activities of faculty members. (b) Information collected as part of this program shall be the sole property of the faculty member. This information or any judgments arising from this program shall not be used to determine non-renewal or termination of a faculty member's contract, suspension or dismissal of a faculty member, denial of advancement on the salary scale, nor affect any other administrative decisions pertaining to the promotion or employment status of the faculty member. (c) A joint advisory committee consisting of three regular faculty members who shall be elected by and are P.D. Committee Chairpersons and three administrators shall make recommendations for the operation, financing and management of the Professional Development Program.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!